Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials - PubMed (original) (raw)
Review
Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials
Harikrishna Makani et al. BMJ. 2013.
Abstract
Objective: To compare the long term efficacy and adverse events of dual blockade of the renin-angiotensin system with monotherapy.
Design: Systematic review and meta-analysis.
Data sources: PubMed, Embase, and the Cochrane central register of controlled trials, January 1990 to August 2012.
Study selection: Randomised controlled trials comparing dual blockers of the renin-angiotensin system with monotherapy, reporting data on either long term efficacy (≥ 1 year) or safety events (≥ 4 weeks), and with a sample size of at least 50. Analysis was stratified by trials with patients with heart failure versus patients without heart failure.
Results: 33 randomised controlled trials with 68,405 patients (mean age 61 years, 71% men) and mean duration of 52 weeks were included. Dual blockade of the renin-angiotensin system was not associated with any significant benefit for all cause mortality (relative risk 0.97, 95% confidence interval 0.89 to 1.06) and cardiovascular mortality (0.96, 0.88 to 1.05) compared with monotherapy. Compared with monotherapy, dual therapy was associated with an 18% reduction in admissions to hospital for heart failure (0.82, 0.74 to 0.92). However, compared with monotherapy, dual therapy was associated with a 55% increase in the risk of hyperkalaemia (P<0.001), a 66% increase in the risk of hypotension (P<0.001), a 41% increase in the risk of renal failure (P=0.01), and a 27% increase in the risk of withdrawal owing to adverse events (P<0.001). Efficacy and safety results were consistent in cohorts with and without heart failure when dual therapy was compared with monotherapy except for all cause mortality, which was higher in the cohort without heart failure (P=0.04 v P=0.15), and renal failure was significantly higher in the cohort with heart failure (P<0.001 v P=0.79).
Conclusion: Although dual blockade of the renin-angiotensin system may have seemingly beneficial effects on certain surrogate endpoints, it failed to reduce mortality and was associated with an excessive risk of adverse events such as hyperkalaemia, hypotension, and renal failure compared with monotherapy. The risk to benefit ratio argues against the use of dual therapy.
Conflict of interest statement
Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi\_disclosure.pdf (available on request from the corresponding author) and declare: FHM is an ad hoc consultant and speaker for Novartis, Daiichi Sankyo, Pfizer, Takeda, Abbott, Medtronic, Servier, and Bayer; SB is on the advisory board of Daiichi Sankyo and Boehringer Ingelheim; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.
Figures
Fig 1 Selection of studies. ACE=angiotensin converting enzyme inhibitor
Fig 2 Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for all cause mortality. Error bars represent 95% confidence intervals and data marker sizes indicate sample sizes of cohorts. ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; DRI=direct renin inhibitor, M-H=Mantel-Haenszel
Fig 3 Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for cardiovascular mortality. ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; DRI=direct renin inhibitor, M-H=Mantel-Haenszel
Fig 4 Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for admissions to hospital for heart failure. ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; DRI=direct renin inhibitor, M-H=Mantel-Haenszel
Fig 5 Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for hyperkalaemia. ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; M-H=Mantel-Haenszel
Fig 6 Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for hypotension, ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; DRI=direct renin inhibitor, M-H=Mantel-Haenszel
Fig 7 Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for renal failure. ACEi=angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blocker; DRI=direct renin inhibitor, M-H=Mantel-Haenszel
Fig 8 Comparison of dual blockade of the renin-angiotensin system (RAS) with monotherapy for withdrawal owing to drug related to adverse events
Comment in
- Authors' reply to Laragh and Sealey.
Messerli FH, Makani H, Bangalore S. Messerli FH, et al. BMJ. 2013 Mar 19;346:f1689. doi: 10.1136/bmj.f1689. BMJ. 2013. PMID: 23512454 No abstract available. - Renin-angiotensin system: Meta-analyses can misdirect decisions on treatment.
Ruggenenti P, Remuzzi G. Ruggenenti P, et al. Nat Rev Nephrol. 2013 Jun;9(6):311-2. doi: 10.1038/nrneph.2013.82. Epub 2013 Apr 30. Nat Rev Nephrol. 2013. PMID: 23629638 No abstract available. - [Be careful when combining ACE inhibitors and angiotensin receptor blockers].
Markun S. Markun S. Praxis (Bern 1994). 2013 May 22;102(11):689-90. doi: 10.1024/1661-8157/a001302. Praxis (Bern 1994). 2013. PMID: 23692910 German. No abstract available.
Similar articles
- Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
Feng Y, Huang R, Kavanagh J, Li L, Zeng X, Li Y, Fu P. Feng Y, et al. Am J Cardiovasc Drugs. 2019 Jun;19(3):259-286. doi: 10.1007/s40256-018-00321-5. Am J Cardiovasc Drugs. 2019. PMID: 30737754 - [Risks of dual blockade of the renin-angiotensin system compared with monotherapy: a systematic review and cumulative meta-analysis of randomized trials and observational studies].
Catalá-López F, Macías Saint-Gerons D, de la Fuente Honrubia C, Martín-Serrano G. Catalá-López F, et al. Rev Esp Salud Publica. 2014 Jan-Feb;88(1):37-65. doi: 10.4321/S1135-57272014000100004. Rev Esp Salud Publica. 2014. PMID: 24728391 Review. Spanish. - Combined blockade of renin-angiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review.
Li SM, He WB, Chen J, Cai QQ, Huang FF, Zhang K, Wang JF, Liu X, Huang H. Li SM, et al. Atherosclerosis. 2018 Feb;269:35-41. doi: 10.1016/j.atherosclerosis.2017.12.009. Epub 2017 Dec 6. Atherosclerosis. 2018. PMID: 29258005 - Renin-Angiotensin System Blockade and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Meta-analysis of Randomized Controlled Trials.
Hiremath S, Fergusson DA, Fergusson N, Bennett A, Knoll GA. Hiremath S, et al. Am J Kidney Dis. 2017 Jan;69(1):78-86. doi: 10.1053/j.ajkd.2016.08.018. Epub 2016 Oct 4. Am J Kidney Dis. 2017. PMID: 27712852 Review. - Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
Werner C, Pöss J, Böhm M. Werner C, et al. Drugs. 2010 Jul 9;70(10):1215-30. doi: 10.2165/11537910-000000000-00000. Drugs. 2010. PMID: 20568830 Review.
Cited by
- The burden of hyperkalaemia on hospital healthcare resources.
Logan Ellis H, Al-Agil M, Kelly PA, Teo J, Sharpe C, Whyte MB. Logan Ellis H, et al. Clin Exp Med. 2024 Aug 13;24(1):190. doi: 10.1007/s10238-024-01452-7. Clin Exp Med. 2024. PMID: 39136879 Free PMC article. - 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association.
Moon JS, Kang S, Choi JH, Lee KA, Moon JH, Chon S, Kim DJ, Kim HJ, Seo JA, Kim MK, Lim JH, Song YJ, Yang YS, Kim JH, Lee YB, Noh J, Hur KY, Park JS, Rhee SY, Kim HJ, Kim HM, Ko JH, Kim NH, Kim CH, Ahn J, Oh TJ, Kim SK, Kim J, Han E, Jin SM, Bae J, Jeon E, Kim JM, Kang SM, Park JH, Yun JS, Cha BS, Moon MK, Lee BW. Moon JS, et al. Diabetes Metab J. 2024 Jul;48(4):546-708. doi: 10.4093/dmj.2024.0249. Epub 2024 Jul 26. Diabetes Metab J. 2024. PMID: 39091005 Free PMC article. No abstract available. - Vitamin D: A Bridge between Kidney and Heart.
Secondulfo C, Visco V, Virtuoso N, Fortunato M, Migliarino S, Rispoli A, La Mura L, Stellato A, Caliendo G, Settembre E, Galluccio F, Hamzeh S, Bilancio G. Secondulfo C, et al. Life (Basel). 2024 May 10;14(5):617. doi: 10.3390/life14050617. Life (Basel). 2024. PMID: 38792638 Free PMC article. Review. - 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024.
American Diabetes Association Professional Practice Committee. American Diabetes Association Professional Practice Committee. Diabetes Care. 2024 Jan 1;47(Suppl 1):S179-S218. doi: 10.2337/dc24-S010. Diabetes Care. 2024. PMID: 38078592 Review.
References
- Menard J, Campbell DJ, Azizi M, Gonzales MF. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 1997;96:3072-8. - PubMed
- Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016. - PubMed
- McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;14:803-69. - PubMed
- Banerjee S, Kaye S. The role of targeted therapy in ovarian cancer. Eur J Cancer 2011;47(Suppl 3):S116-30. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources